Compare BridgeBio Pharma Inc (BBIO) vs GE Aerospace (GE) Price & Performance

BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.

Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.

GE trades at $353.73, down 1.54% today, with a bullish technical signal from moving averages and oversold RSI levels. The company reported strong Q1 2026 earnings of $1.86 per share, beating estimates, supported by robust aerospace demand and defense contract wins. Revenue grew to $45.86 billion in 2025, with net income margins improving to 17.86%. Analysts maintain a bullish consensus with a $397 price target, citing order growth and backlog strength.

Outlook remains positive due to aerospace momentum and strategic investments, but high valuation ratios (P/E 43.9) and debt levels pose risks. The stock offers upside to consensus targets, though investors should monitor execution on growth initiatives and macroeconomic pressures on defense spending.